Foley & Lardner LLP Partner Thomas (T.J.) Ferrante is quoted in the Kaiser Health News article, “Digital Mental Health Companies Draw Scrutiny and Growing Concerns,” about the legal difficulties mental health telemedicine companies face, particularly as they relate to prescription protocols and advertising.
Ferrante, who represents online health care companies, describes the recent federal investigation into one company for possible violations of the Controlled Substances Act, as “a wake-up call to everyone in the industry. It is a reminder that health care is a highly regulated space.”
The article also ran in the Los Angeles Times, Fierce Biotech, WebMD, and other outlets.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”